The global DNA methylation sequencing market was valued at USD 1.46 billion in 2025. The market is estimated at USD 1.72 billion in 2026 and is projected to reach USD 6.48 billion by 2036, at a CAGR of 14.2% during the forecast period 2026-2036. This report provides a detailed assessment of the market, covering conversion and sequencing chemistries, cell-free DNA (cfDNA) methylation, clinical evidence from screening trials, regulation and reimbursement, cost per test, and the supplier landscape.
The market covers kits and reagents, instruments, software, and services for sequencing-based mapping of cytosine methylation, mainly 5-methylcytosine (5mC), across whole genomes or selected regions. Abnormal methylation patterns are linked to cancer, aging, neurological disorders, and rare diseases. Covered products range from bisulfite kits for WGBS, RRBS, and targeted work to newer conversion chemistries such as EM-seq, Illumina's 5-Base Solution, and biomodal's duet, along with library and enrichment kits, sequencers, analysis software, and research and clinical testing services. Methylation microarrays, PCR-based methylation assays, histone and chromatin profiling, and sequencing done without methylation analysis are excluded.
At the May 2026 annual meeting of the American Society of Clinical Oncology (ASCO), NHS-Galleri investigators reported that Galleri found 937 cancers, about 40% of them at Stage I-II, with 22% and 26% fewer Stage IV diagnoses of 12 aggressive cancers in the second and third screening rounds, and the PATHFINDER 2 study reported a 6.5-fold rise in cancers found versus standard screening. Commercial volumes are rising quickly: GRAIL reported more than 61,000 Galleri tests in the second quarter of 2026, up 35%, and Guardant Health reported about 66,000 Shield tests, up from about 16,000 a year earlier, with 2026 guidance of 270,000 to 285,000 tests.
Whole-genome methylation sequencing needs deep coverage across millions of CpG sites, which keeps it far more expensive than many targeted genetic tests and pushes many laboratories toward targeted or reduced representation methods, especially in academia and emerging economies. Clinical tests face tough regulatory and payer hurdles; GRAIL has filed a premarket approval (PMA) application with the FDA and expects an advisory committee meeting in fall 2026, while NHS-Galleri fell short of statistical significance on its combined Stage III-IV endpoint. Data analysis is complex and poorly standardized across chemistries and platforms, and sensitivity for Stage I cancers remains limited because early tumors shed little DNA into blood.
Multi-cancer early detection is a major opportunity, as many cancers have no recommended screening test; in PATHFINDER 2, nearly half of newly found cancers fell into that group. Lower-cost workflows open further room, and Guardant Health is rolling out an FDA-approved, methylation-only Shield workflow that it expects to cut costs by about 15% by the end of 2026. Epigenetic clocks in aging research and methylation analysis of imprinting and repeat expansion disorders are other openings. Key trends include the shift from bisulfite to enzymatic and chemical conversion, combined genomic and epigenomic analysis in one workflow, and a shift of volume from research into clinical laboratories.
By offering, the DNA methylation sequencing market is segmented into kits & reagents, instruments, software & bioinformatics, and services. Kits & reagents are expected to account for the largest share in 2026, as conversion, library, and enrichment products are consumed in every experiment and test, and methylation analysis is widely used across research and clinical laboratories. Services are expected to grow at the highest CAGR, driven by fast-growing clinical test volumes for Galleri and Shield, which are run as laboratory services, and by research institutions and drug developers outsourcing whole-genome and targeted methylation work. Software & bioinformatics should grow strongly as labs need specialized pipelines and classifiers.
By technology, the DNA methylation sequencing market is segmented into bisulfite sequencing (WGBS, RRBS, and targeted), enzymatic & chemical conversion sequencing, long-read native methylation sequencing, and other technologies. Bisulfite sequencing is expected to account for the largest share in 2026, as it remains the reference method, kits and analysis tools are widely available, and many existing research and clinical workflows are built on it. Enzymatic & chemical conversion sequencing is expected to grow at the highest CAGR, as these methods preserve DNA, give better libraries from low-input samples such as cfDNA, and have gained new products such as the Illumina 5-Base Solution and biomodal's duet portfolio. Long-read native methylation sequencing should grow strongly as long-read genomes get cheaper.
By approach, the DNA methylation sequencing market is segmented into targeted methylation sequencing, whole-genome methylation sequencing, and reduced representation methylation sequencing. Targeted methylation sequencing is expected to account for the largest share in 2026, since screening and diagnostic tests such as Galleri use targeted panels to reach deep coverage of informative regions at an affordable cost. Whole-genome methylation sequencing is expected to grow at the highest CAGR, supported by lower sequencing costs, whole-genome products that return genetic and epigenetic data together, and native methylation calls from long-read genomes. Reduced representation remains a low-cost research option.
By sample type, the DNA methylation sequencing market is segmented into blood & cell-free DNA, tissue, and other samples. Blood & cell-free DNA is expected to account for the largest share in 2026 and to grow at the highest CAGR during the forecast period, as liquid biopsy tests for screening, diagnosis, and monitoring are scaling quickly, and blood samples are also used in aging and population health research. Tissue remains important in tumor research and classification.
By application, the DNA methylation sequencing market is segmented into oncology (cancer screening & early detection, diagnosis & monitoring, and cancer research), genetic & rare diseases, neurological disorders, aging & biological age research, reproductive & developmental biology, and other applications. Oncology is expected to account for the largest share in 2026, since methylation changes are a hallmark of tumors and liquid biopsy volumes are climbing fast. Within oncology, cancer screening & early detection is expected to grow at the highest CAGR, driven by rising Galleri and Shield volumes, the Galleri PMA filing, and work on multi-cancer detection. Aging & biological age research is also set for strong growth as epigenetic clocks are used to study aging and preventive health.
By end user, the DNA methylation sequencing market is segmented into academic & research institutes, diagnostic laboratories, pharmaceutical & biotechnology companies, hospitals & clinics, and other end users. Academic & research institutes are expected to account for the largest share in 2026, as universities carry out much of the world's epigenetic research across cancer, neuroscience, and development. Diagnostic laboratories are expected to grow at the highest CAGR, driven by the fast growth of methylation-based screening and diagnostic testing and the need for automated, high-throughput clinical workflows. Drug developers use methylation data in biomarker programs.
North America is set to hold the largest share of the DNA methylation sequencing market in 2026, owing to commercially available methylation-based screening tests, strong research funding, and home-based firms such as Illumina, GRAIL, PacBio, Guardant Health, Twist Bioscience, New England Biolabs, and Zymo Research. In the U.S., an FDA decision on Galleri could widen clinical use further, while Canada adds demand through academic research and clinical genetics. Europe holds a significant share, supported by strong academic research, large clinical trials, and U.K.-based suppliers Oxford Nanopore Technologies and biomodal; the U.K. stands out because the NHS-Galleri trial, the largest randomized trial of a multi-cancer test, has screened more than 140,000 people. Germany, France, the Netherlands, and Spain also contribute through cancer and epigenetic research.
Asia-Pacific is projected to post the highest CAGR through 2036, owing to large and aging populations, a high burden of liver, gastric, esophageal, colorectal, and lung cancers, growing screening programs, and rising investment in genomics. China is expected to hold the largest share in the region, helped by a strong genomics industry and locally developed methylation-based cancer tests, although Oxford Nanopore reported first-half 2026 sales in China down 16%, a decline that reflects trade and market access hurdles. Japan, South Korea, Singapore, Australia, and India should grow strongly. Latin America, led by Brazil and Mexico, and the Middle East & Africa, where Saudi Arabia, the UAE, and Qatar run genomic medicine programs, hold smaller shares.
The DNA methylation sequencing market is moderately consolidated, as leading sequencing platform makers and reagent suppliers hold a significant share of research demand while a few clinical test developers lead methylation-based screening and diagnostics. Competition centers on conversion efficiency, low-input sensitivity, cost per sample, combined genetic and epigenetic readouts, software, clinical evidence, and approvals. Recent developments include Illumina's October 2025 launch of the 5-Base Solution, the February 2026 move to make biomodal's duet solutions compatible with Element Biosciences' AVITI sequencers, PacBio's 2026 SPRQ-Nx rollout, the May 2026 ASCO presentation of NHS-Galleri and PATHFINDER 2 data, GRAIL's PMA filing, and Guardant Health's August 2026 launch of a methylation-only Shield workflow.
Key companies profiled in the report include Illumina, Inc. (U.S.), Pacific Biosciences of California, Inc. (U.S.), Oxford Nanopore Technologies plc (U.K.), New England Biolabs, Inc. (U.S.), Zymo Research Corporation (U.S.), Agilent Technologies, Inc. (U.S.), QIAGEN N.V. (Netherlands), Twist Bioscience Corporation (U.S.), biomodal Limited (U.K.), GRAIL, Inc. (U.S.), and Guardant Health, Inc. (U.S.).
The market covers kits and reagents, instruments, software, and services for sequencing-based mapping of cytosine methylation, mainly 5-methylcytosine (5mC), across whole genomes or selected regions. Abnormal methylation patterns are linked to cancer, aging, neurological disorders, and rare diseases. Covered products range from bisulfite kits for WGBS, RRBS, and targeted work to newer conversion chemistries such as EM-seq, Illumina's 5-Base Solution, and biomodal's duet, along with library and enrichment kits, sequencers, analysis software, and research and clinical testing services. Methylation microarrays, PCR-based methylation assays, histone and chromatin profiling, and sequencing done without methylation analysis are excluded.
At the May 2026 annual meeting of the American Society of Clinical Oncology (ASCO), NHS-Galleri investigators reported that Galleri found 937 cancers, about 40% of them at Stage I-II, with 22% and 26% fewer Stage IV diagnoses of 12 aggressive cancers in the second and third screening rounds, and the PATHFINDER 2 study reported a 6.5-fold rise in cancers found versus standard screening. Commercial volumes are rising quickly: GRAIL reported more than 61,000 Galleri tests in the second quarter of 2026, up 35%, and Guardant Health reported about 66,000 Shield tests, up from about 16,000 a year earlier, with 2026 guidance of 270,000 to 285,000 tests.
Market Dynamics
Methylation-based liquid biopsy for cancer screening is the main driver of the DNA methylation sequencing market, because methylation marks in cfDNA can reveal both the presence of cancer and its tissue of origin from a single blood draw, and each test needs conversion, enrichment, sequencing, and analysis. Methylation is also used more in diagnosis and monitoring. In PATHFINDER 2, GRAIL reported that Galleri pinpointed where the cancer signal came from in over 90% of cases, and Guardant360 Liquid CDx blends genomic with epigenomic content. New bisulfite-free chemistries protect DNA and read variants and methylation together, while long-read platforms from PacBio and Oxford Nanopore detect 5mC directly from native DNA, with PacBio's SPRQ-Nx chemistry priced at USD 345 per genome.Whole-genome methylation sequencing needs deep coverage across millions of CpG sites, which keeps it far more expensive than many targeted genetic tests and pushes many laboratories toward targeted or reduced representation methods, especially in academia and emerging economies. Clinical tests face tough regulatory and payer hurdles; GRAIL has filed a premarket approval (PMA) application with the FDA and expects an advisory committee meeting in fall 2026, while NHS-Galleri fell short of statistical significance on its combined Stage III-IV endpoint. Data analysis is complex and poorly standardized across chemistries and platforms, and sensitivity for Stage I cancers remains limited because early tumors shed little DNA into blood.
Multi-cancer early detection is a major opportunity, as many cancers have no recommended screening test; in PATHFINDER 2, nearly half of newly found cancers fell into that group. Lower-cost workflows open further room, and Guardant Health is rolling out an FDA-approved, methylation-only Shield workflow that it expects to cut costs by about 15% by the end of 2026. Epigenetic clocks in aging research and methylation analysis of imprinting and repeat expansion disorders are other openings. Key trends include the shift from bisulfite to enzymatic and chemical conversion, combined genomic and epigenomic analysis in one workflow, and a shift of volume from research into clinical laboratories.
Segment Analysis
The report analyzes the market by offering, technology, approach, sample type, application, end user, and geography, helping stakeholders identify the most attractive areas for product development, partnering, and investment.By offering, the DNA methylation sequencing market is segmented into kits & reagents, instruments, software & bioinformatics, and services. Kits & reagents are expected to account for the largest share in 2026, as conversion, library, and enrichment products are consumed in every experiment and test, and methylation analysis is widely used across research and clinical laboratories. Services are expected to grow at the highest CAGR, driven by fast-growing clinical test volumes for Galleri and Shield, which are run as laboratory services, and by research institutions and drug developers outsourcing whole-genome and targeted methylation work. Software & bioinformatics should grow strongly as labs need specialized pipelines and classifiers.
By technology, the DNA methylation sequencing market is segmented into bisulfite sequencing (WGBS, RRBS, and targeted), enzymatic & chemical conversion sequencing, long-read native methylation sequencing, and other technologies. Bisulfite sequencing is expected to account for the largest share in 2026, as it remains the reference method, kits and analysis tools are widely available, and many existing research and clinical workflows are built on it. Enzymatic & chemical conversion sequencing is expected to grow at the highest CAGR, as these methods preserve DNA, give better libraries from low-input samples such as cfDNA, and have gained new products such as the Illumina 5-Base Solution and biomodal's duet portfolio. Long-read native methylation sequencing should grow strongly as long-read genomes get cheaper.
By approach, the DNA methylation sequencing market is segmented into targeted methylation sequencing, whole-genome methylation sequencing, and reduced representation methylation sequencing. Targeted methylation sequencing is expected to account for the largest share in 2026, since screening and diagnostic tests such as Galleri use targeted panels to reach deep coverage of informative regions at an affordable cost. Whole-genome methylation sequencing is expected to grow at the highest CAGR, supported by lower sequencing costs, whole-genome products that return genetic and epigenetic data together, and native methylation calls from long-read genomes. Reduced representation remains a low-cost research option.
By sample type, the DNA methylation sequencing market is segmented into blood & cell-free DNA, tissue, and other samples. Blood & cell-free DNA is expected to account for the largest share in 2026 and to grow at the highest CAGR during the forecast period, as liquid biopsy tests for screening, diagnosis, and monitoring are scaling quickly, and blood samples are also used in aging and population health research. Tissue remains important in tumor research and classification.
By application, the DNA methylation sequencing market is segmented into oncology (cancer screening & early detection, diagnosis & monitoring, and cancer research), genetic & rare diseases, neurological disorders, aging & biological age research, reproductive & developmental biology, and other applications. Oncology is expected to account for the largest share in 2026, since methylation changes are a hallmark of tumors and liquid biopsy volumes are climbing fast. Within oncology, cancer screening & early detection is expected to grow at the highest CAGR, driven by rising Galleri and Shield volumes, the Galleri PMA filing, and work on multi-cancer detection. Aging & biological age research is also set for strong growth as epigenetic clocks are used to study aging and preventive health.
By end user, the DNA methylation sequencing market is segmented into academic & research institutes, diagnostic laboratories, pharmaceutical & biotechnology companies, hospitals & clinics, and other end users. Academic & research institutes are expected to account for the largest share in 2026, as universities carry out much of the world's epigenetic research across cancer, neuroscience, and development. Diagnostic laboratories are expected to grow at the highest CAGR, driven by the fast growth of methylation-based screening and diagnostic testing and the need for automated, high-throughput clinical workflows. Drug developers use methylation data in biomarker programs.
Regional Analysis
The report covers North America, Asia-Pacific, Europe, Latin America, and the Middle East & Africa, spanning 19 countries and four rest-of-region groups. The regional analysis of the DNA methylation sequencing market considers test availability, reimbursement, screening programs, research funding, and cancer burden.North America is set to hold the largest share of the DNA methylation sequencing market in 2026, owing to commercially available methylation-based screening tests, strong research funding, and home-based firms such as Illumina, GRAIL, PacBio, Guardant Health, Twist Bioscience, New England Biolabs, and Zymo Research. In the U.S., an FDA decision on Galleri could widen clinical use further, while Canada adds demand through academic research and clinical genetics. Europe holds a significant share, supported by strong academic research, large clinical trials, and U.K.-based suppliers Oxford Nanopore Technologies and biomodal; the U.K. stands out because the NHS-Galleri trial, the largest randomized trial of a multi-cancer test, has screened more than 140,000 people. Germany, France, the Netherlands, and Spain also contribute through cancer and epigenetic research.
Asia-Pacific is projected to post the highest CAGR through 2036, owing to large and aging populations, a high burden of liver, gastric, esophageal, colorectal, and lung cancers, growing screening programs, and rising investment in genomics. China is expected to hold the largest share in the region, helped by a strong genomics industry and locally developed methylation-based cancer tests, although Oxford Nanopore reported first-half 2026 sales in China down 16%, a decline that reflects trade and market access hurdles. Japan, South Korea, Singapore, Australia, and India should grow strongly. Latin America, led by Brazil and Mexico, and the Middle East & Africa, where Saudi Arabia, the UAE, and Qatar run genomic medicine programs, hold smaller shares.
Competitive Landscape
The report provides a detailed review of the competitive landscape, covering key growth strategies, competitive benchmarking, the competitive dashboard, and market share/rank analysis by key player for 2025, together with company profiles covering business and financial overviews, portfolios, developments, and SWOT analyses.The DNA methylation sequencing market is moderately consolidated, as leading sequencing platform makers and reagent suppliers hold a significant share of research demand while a few clinical test developers lead methylation-based screening and diagnostics. Competition centers on conversion efficiency, low-input sensitivity, cost per sample, combined genetic and epigenetic readouts, software, clinical evidence, and approvals. Recent developments include Illumina's October 2025 launch of the 5-Base Solution, the February 2026 move to make biomodal's duet solutions compatible with Element Biosciences' AVITI sequencers, PacBio's 2026 SPRQ-Nx rollout, the May 2026 ASCO presentation of NHS-Galleri and PATHFINDER 2 data, GRAIL's PMA filing, and Guardant Health's August 2026 launch of a methylation-only Shield workflow.
Key companies profiled in the report include Illumina, Inc. (U.S.), Pacific Biosciences of California, Inc. (U.S.), Oxford Nanopore Technologies plc (U.K.), New England Biolabs, Inc. (U.S.), Zymo Research Corporation (U.S.), Agilent Technologies, Inc. (U.S.), QIAGEN N.V. (Netherlands), Twist Bioscience Corporation (U.S.), biomodal Limited (U.K.), GRAIL, Inc. (U.S.), and Guardant Health, Inc. (U.S.).
How This Report Helps
- Provides reliable market size estimates and long-term forecasts for the global DNA methylation sequencing market.
- Explains how methylation-based cancer screening, liquid biopsy, new conversion chemistries, and long-read sequencing are driving demand.
- Assesses the impact of whole-genome costs, regulatory and reimbursement hurdles, and early-stage sensitivity limits.
- Identifies high-growth opportunities across offering, technology, approach, sample type, application, end user, and region.
- Tracks multi-cancer detection, epigenetic aging, and rare disease uses.
- Benchmarks leading companies by chemistry, platform, clinical evidence, test volumes, and regulatory progress.
- Supports product planning, partnering, and market entry decisions for suppliers, test developers, and investors.
Key Questions Answered
- How big is the global DNA methylation sequencing market today, and how will it grow through 2036?
- How are methylation-based screening tests such as Galleri and Shield changing demand for sequencing?
- What are the main drivers, restraints, opportunities, challenges, and trends shaping the market?
- How fast will enzymatic and chemical conversion replace bisulfite sequencing?
- Which offering, technology, approach, sample type, application, and end user segments will grow the fastest?
- What do NHS-Galleri and PATHFINDER 2 results mean for multi-cancer early detection?
- Which regions and countries offer the most attractive business opportunities?
- Who are the leading companies in the market, and what strategies are they using?
Table of Contents
1. Introduction
2. Research Methodology
4. Market Overview
5. DNA Methylation Sequencing Market, by Offering
6. DNA Methylation Sequencing Market, by Technology
7. DNA Methylation Sequencing Market, by Approach
8. DNA Methylation Sequencing Market, by Sample Type
9. DNA Methylation Sequencing Market, by Application
10. DNA Methylation Sequencing Market, by End User
11. DNA Methylation Sequencing Market, by Geography
12. Competitive Landscape
13. Company Profiles
14. Appendix
LIST OF TABLES
LIST OF FIGURES
Companies Mentioned
- Illumina, Inc.
- Pacific Biosciences of California, Inc.
- Oxford Nanopore Technologies plc
- New England Biolabs, Inc.
- Zymo Research Corporation
- Agilent Technologies, Inc.
- QIAGEN N.V.
- Twist Bioscience Corporation
- biomodal Limited
- GRAIL, Inc.
- Guardant Health, Inc.
